# Sodium Danshensu promotes diabetic wound healing by targeting the EGFR-mediated PI3K-AKT pathway: a combined network pharmacology, machine learning, and in vitro approach

**Authors:** Peng Ning, Fan Yang, Hongyi Cao, Bo Zhou

PMC · DOI: 10.1039/d5ra09417h · 2026-03-10

## TL;DR

Sodium Danshensu helps heal diabetic wounds by activating a key cell signaling pathway, reducing inflammation, and improving blood vessel growth.

## Contribution

This study identifies EGFR as a novel target of Sodium Danshensu in diabetic wound healing through network pharmacology and machine learning.

## Key findings

- SDSS activates the PI3K-AKT pathway via EGFR, promoting endothelial cell migration and angiogenesis.
- SDSS reduces oxidative stress and inflammatory factors in high-glucose conditions.
- Molecular docking and in vitro experiments confirm SDSS's interaction with EGFR and therapeutic effects.

## Abstract

Sodium Danshensu (SDSS) shows potential in treating diabetic wounds (DWs) owing to its antioxidant, anti-inflammatory, and pro-angiogenesis effects. The specific pharmacological mechanisms of SDSS in achieving the above effects were evaluated. The potential targets of SDSS and DWs were obtained from online databases. Interaction networks were constructed using network pharmacology, and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Combined with machine learning, the biological targets were evaluated and prioritized. A high-glucose-induced human umbilical vein endothelial cell (HUVEC) model was established for in vitro studies. A total of 126 shared targets of SDSS and DWs were selected, and the core targets included EGFR, CASP3, SRC, ESR1, JUN, NFKB1, IGF1R, ESR2, AR, and PPARG. KEGG enrichment analysis revealed significant enrichment of the PI3K-AKT signaling pathway (P < 0.05). Machine learning indicated EGFR as a key target of SDSS in treating DWs. Findings from molecular docking and molecular dynamics simulation confirmed the stable combination of SDSS and EGFR. In vitro experiments indicated that SDSS may activate the PI3K-AKT pathway via EGFR targets, improve the mobility of high-glucose-induced HUVECs, and increase lumen formation (branch number). It promoted catalase production and inhibited the release of malondialdehyde and inflammatory factors including tumor necrosis factor-α and interleukin-6 (all P < 0.05). SDSS activates the PI3K-AKT pathway via EGFR, promotes endothelial cell migration and angiogenesis, and inhibits oxidative stress and the inflammatory response, highlighting its potential in treating DWs.

Sodium Danshensu (SDSS) shows potential in treating diabetic wounds (DWs) owing to its antioxidant, anti-inflammatory, and pro-angiogenesis effects.

## Linked entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956], CASP3 (caspase 3) [NCBI Gene 836], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714], ESR1 (estrogen receptor 1) [NCBI Gene 2099], JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480], ESR2 (estrogen receptor 2) [NCBI Gene 2100], AR (androgen receptor) [NCBI Gene 367], PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468]
- **Chemicals:** Sodium Danshensu (PubChem CID 23711819), malondialdehyde (PubChem CID 10964)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ESR2 (estrogen receptor 2) [NCBI Gene 2100] {aka ER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CAT (catalase) [NCBI Gene 847], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480] {aka CD221, IGFIR, IGFR, JTK13}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}
- **Diseases:** DWs (MESH:D003920), inflammatory (MESH:D007249), SDSS (MESH:C562576)
- **Chemicals:** malondialdehyde (MESH:D008315), SDSS (-)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12972934/full.md

---
Source: https://tomesphere.com/paper/PMC12972934